GEN Exclusives

More »

GEN News Highlights

More »
Oct 26, 2011

Sanofi to Investigate Immune Design’s TLR-4 Agonist Platform in the Field of Allergy

  • Immune Design (IDC) entered into a research collaboration with Sanofi focused on allergy. Sanofi will evaluate IDC's GLA (glucopyranosyl lipid adjuvant) technology, a toll-like receptor 4 (TLR-4) agonist.

    "The application of next-generation TLR-4 agonists able to shape the immune response in allergic disease has enormous therapeutic potential,” states IDC CEO Carlos Paya, M.D., Ph.D. “Our initial collaboration has the strong possibility to lead to a broader development-focused partnership with Sanofi in the near future."

    Under terms of the agreement, IDC will provide access to the GLA technology, allowing Sanofi the ability to evaluate the biological and immunological properties of this TLR-4 agonist in vitro and in allergy disease models. Sanofi will be granted an option to select lead candidates for further development. 

    The technology can be used to promote optimal activation of human dendritic cells, has demonstrated compatibility with many antigens, and has a well-established safety profile to date, according to IDC. GLA was shown to be safe and well-tolerated in a Phase I study in combination with Fluzone (a flu vaccine), according to IDC.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Patients Access to Experimental Medicines?

More »